SK8752002A3 - Substituted N-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect - Google Patents

Substituted N-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect Download PDF

Info

Publication number: SK8752002A3
Authority: SK; Slovakia
Prior art keywords: cooh; acid; group; amino; radical
Prior art date: 1999-12-23

Application number

SK875-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Eckhard Gunther

Peter Emig

Dietmar Reichert

Baut Guillaume Le

Bernd Nickel

Gerald Bacher

Original Assignee

Zentaris Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-23

Filing date

2000-12-19

Publication date

2003-01-09

2000-12-19 Application filed by Zentaris Ag filed Critical Zentaris Ag

2003-01-09 Publication of SK8752002A3 publication Critical patent/SK8752002A3/sk

Links

MRDIZANPJLYUKO-UHFFFAOYSA-N 2-(1-benzylindol-3-yl)-2-oxoacetic acid Chemical class C12=CC=CC=C2C(C(=O)C(=O)O)=CN1CC1=CC=CC=C1 MRDIZANPJLYUKO-UHFFFAOYSA-N 0.000 title claims abstract description 5
230000000259 anti-tumor effect Effects 0.000 title claims description 4
150000001875 compounds Chemical class 0.000 claims abstract description 29
239000002253 acid Substances 0.000 claims abstract description 17
150000003839 salts Chemical class 0.000 claims abstract description 13
239000000725 suspension Substances 0.000 claims abstract description 8
239000003085 diluting agent Substances 0.000 claims abstract description 7
238000002360 preparation method Methods 0.000 claims abstract description 4
239000002775 capsule Substances 0.000 claims abstract description 3
239000006071 cream Substances 0.000 claims abstract description 3
239000002674 ointment Substances 0.000 claims abstract description 3
239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 3
150000007522 mineralic acids Chemical class 0.000 claims abstract 2
150000007524 organic acids Chemical class 0.000 claims abstract 2
235000005985 organic acids Nutrition 0.000 claims abstract 2
239000000829 suppository Substances 0.000 claims abstract 2
-1 nitro, amino Chemical group 0.000 claims description 57
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 44
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 14
229910052736 halogen Inorganic materials 0.000 claims description 14
150000002367 halogens Chemical group 0.000 claims description 14
229910052739 hydrogen Inorganic materials 0.000 claims description 13
239000001257 hydrogen Substances 0.000 claims description 13
125000000217 alkyl group Chemical group 0.000 claims description 10
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 9
FVSYLLUZSRCXEH-UHFFFAOYSA-N 2-[1-[(4-aminophenyl)methyl]indol-3-yl]-2-oxo-n-pyridin-4-ylacetamide Chemical compound C1=CC(N)=CC=C1CN1C2=CC=CC=C2C(C(=O)C(=O)NC=2C=CN=CC=2)=C1 FVSYLLUZSRCXEH-UHFFFAOYSA-N 0.000 claims description 8
HRYYIVZPPROGAN-UHFFFAOYSA-N 2-[1-[(4-nitrophenyl)methyl]indol-3-yl]-2-oxo-n-pyridin-4-ylacetamide Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1C2=CC=CC=C2C(C(=O)C(=O)NC=2C=CN=CC=2)=C1 HRYYIVZPPROGAN-UHFFFAOYSA-N 0.000 claims description 8
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 8
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 6
125000004432 carbon atom Chemical group C* 0.000 claims description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
150000002431 hydrogen Chemical class 0.000 claims description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
125000006624 (C1-C6) alkoxycarbonylamino group Chemical group 0.000 claims description 4
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 4
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
150000007513 acids Chemical class 0.000 claims description 4
150000001413 amino acids Chemical class 0.000 claims description 4
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 4
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 4
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 claims description 3
239000002246 antineoplastic agent Substances 0.000 claims description 3
125000005239 aroylamino group Chemical group 0.000 claims description 3
125000006627 ethoxycarbonylamino group Chemical group 0.000 claims description 3
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
125000005862 (C1-C6)alkanoyl group Chemical group 0.000 claims description 2
FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical group C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 2
ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 claims description 2
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims description 2
125000003162 alpha-aspartyl group Chemical group 0.000 claims description 2
125000000337 alpha-glutamyl group Chemical group 0.000 claims description 2
125000006294 amino alkylene group Chemical group 0.000 claims description 2
125000005421 aryl sulfonamido group Chemical group 0.000 claims description 2
235000010323 ascorbic acid Nutrition 0.000 claims description 2
239000011668 ascorbic acid Substances 0.000 claims description 2
229960005070 ascorbic acid Drugs 0.000 claims description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
239000002552 dosage form Substances 0.000 claims description 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
239000001530 fumaric acid Substances 0.000 claims description 2
229940097043 glucuronic acid Drugs 0.000 claims description 2
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 2
229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
239000004310 lactic acid Substances 0.000 claims description 2
235000014655 lactic acid Nutrition 0.000 claims description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
239000011976 maleic acid Substances 0.000 claims description 2
229940098779 methanesulfonic acid Drugs 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
239000011707 mineral Substances 0.000 claims description 2
239000011664 nicotinic acid Substances 0.000 claims description 2
235000001968 nicotinic acid Nutrition 0.000 claims description 2
229960003512 nicotinic acid Drugs 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 2
125000004193 piperazinyl group Chemical group 0.000 claims description 2
239000000843 powder Substances 0.000 claims description 2
125000006239 protecting group Chemical group 0.000 claims description 2
125000005493 quinolyl group Chemical group 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims 2
239000003826 tablet Substances 0.000 claims 2
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims 1
150000001204 N-oxides Chemical class 0.000 claims 1
229960000583 acetic acid Drugs 0.000 claims 1
235000011054 acetic acid Nutrition 0.000 claims 1
125000004093 cyano group Chemical group *C#N 0.000 claims 1
239000000174 gluconic acid Substances 0.000 claims 1
235000012208 gluconic acid Nutrition 0.000 claims 1
229950006191 gluconic acid Drugs 0.000 claims 1
229940093915 gynecological organic acid Drugs 0.000 claims 1
125000000623 heterocyclic group Chemical group 0.000 claims 1
239000003978 infusion fluid Substances 0.000 claims 1
229940098895 maleic acid Drugs 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
230000005748 tumor development Effects 0.000 claims 1
238000001802 infusion Methods 0.000 abstract description 2
239000000126 substance Substances 0.000 abstract description 2
239000002671 adjuvant Substances 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000001173 tumoral effect Effects 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 48
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
239000000203 mixture Substances 0.000 description 17
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 15
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
239000002904 solvent Substances 0.000 description 12
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
239000012299 nitrogen atmosphere Substances 0.000 description 10
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 10
239000003054 catalyst Substances 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 9
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
238000005984 hydrogenation reaction Methods 0.000 description 8
239000000010 aprotic solvent Substances 0.000 description 7
238000000034 method Methods 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 6
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
239000000741 silica gel Substances 0.000 description 6
229910002027 silica gel Inorganic materials 0.000 description 6
239000007868 Raney catalyst Substances 0.000 description 5
229910000564 Raney nickel Inorganic materials 0.000 description 5
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
125000003710 aryl alkyl group Chemical group 0.000 description 4
238000004440 column chromatography Methods 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 4
239000012454 non-polar solvent Substances 0.000 description 4
239000003960 organic solvent Substances 0.000 description 4
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
230000035484 reaction time Effects 0.000 description 4
150000003335 secondary amines Chemical class 0.000 description 4
238000003756 stirring Methods 0.000 description 4
AWMLDBKLOPNOAR-UHFFFAOYSA-N 2-(1h-indol-3-yl)-2-oxoacetamide Chemical class C1=CC=C2C(C(=O)C(=O)N)=CNC2=C1 AWMLDBKLOPNOAR-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
125000003118 aryl group Chemical group 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000003480 eluent Substances 0.000 description 3
125000004475 heteroaralkyl group Chemical group 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000002516 radical scavenger Substances 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000002002 slurry Substances 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
RVPTXIBMGYNFNG-UHFFFAOYSA-N 1-[(4-nitrophenyl)methyl]indole Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1C2=CC=CC=C2C=C1 RVPTXIBMGYNFNG-UHFFFAOYSA-N 0.000 description 2
BVRCPMXFRMVPNG-UHFFFAOYSA-N 2-(1h-indol-3-yl)-2-oxo-n-pyridin-4-ylacetamide Chemical compound C=1NC2=CC=CC=C2C=1C(=O)C(=O)NC1=CC=NC=C1 BVRCPMXFRMVPNG-UHFFFAOYSA-N 0.000 description 2
NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
238000013019 agitation Methods 0.000 description 2
125000003545 alkoxy group Chemical group 0.000 description 2
125000003282 alkyl amino group Chemical group 0.000 description 2
230000000202 analgesic effect Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229910052802 copper Inorganic materials 0.000 description 2
239000010949 copper Substances 0.000 description 2
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
238000004821 distillation Methods 0.000 description 2
229960004979 fampridine Drugs 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
239000007789 gas Substances 0.000 description 2
125000001072 heteroaryl group Chemical group 0.000 description 2
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
150000002475 indoles Chemical class 0.000 description 2
150000002500 ions Chemical class 0.000 description 2
KGCNHWXDPDPSBV-UHFFFAOYSA-N p-nitrobenzyl chloride Chemical compound [O-][N+](=O)C1=CC=C(CCl)C=C1 KGCNHWXDPDPSBV-UHFFFAOYSA-N 0.000 description 2
229910052697 platinum Inorganic materials 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
150000003141 primary amines Chemical class 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
239000003586 protic polar solvent Substances 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
238000010992 reflux Methods 0.000 description 2
ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
229910000029 sodium carbonate Inorganic materials 0.000 description 2
238000001665 trituration Methods 0.000 description 2
239000008096 xylene Substances 0.000 description 2
YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
SIYIBWRIGSGXKY-UHFFFAOYSA-N 2-(1h-indol-2-yl)-2-oxoacetamide Chemical class C1=CC=C2NC(C(=O)C(=O)N)=CC2=C1 SIYIBWRIGSGXKY-UHFFFAOYSA-N 0.000 description 1
DWLVFWDCSFTDOD-UHFFFAOYSA-N 2-(1h-indol-3-yl)-2-oxoacetic acid Chemical class C1=CC=C2C(C(=O)C(=O)O)=CNC2=C1 DWLVFWDCSFTDOD-UHFFFAOYSA-N 0.000 description 1
FPEGGKCNMYDNMW-UHFFFAOYSA-N 2-(1h-indol-3-yl)-2-oxoacetyl chloride Chemical group C1=CC=C2C(C(=O)C(=O)Cl)=CNC2=C1 FPEGGKCNMYDNMW-UHFFFAOYSA-N 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
IQJKJKWFDIYJDV-UHFFFAOYSA-N C(C=O)(=O)NC1=C(N(C2=CC=CC=C12)CC1=CC=C(C=C1)[N+](=O)[O-])C1=CC=NC=C1 Chemical compound C(C=O)(=O)NC1=C(N(C2=CC=CC=C12)CC1=CC=C(C=C1)[N+](=O)[O-])C1=CC=NC=C1 IQJKJKWFDIYJDV-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
102000000587 Glycerolphosphate Dehydrogenase Human genes 0.000 description 1
108010041921 Glycerolphosphate Dehydrogenase Proteins 0.000 description 1
102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
102000029749 Microtubule Human genes 0.000 description 1
108091022875 Microtubule Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010033645 Pancreatitis Diseases 0.000 description 1
206010039085 Rhinitis allergic Diseases 0.000 description 1
102000005473 Secretory Phospholipases A2 Human genes 0.000 description 1
108010031873 Secretory Phospholipases A2 Proteins 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
201000010105 allergic rhinitis Diseases 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000001773 anti-convulsant effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000001754 anti-pyretic effect Effects 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
238000005574 benzylation reaction Methods 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000000460 chlorine Chemical group 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
AMANDCZTVNQSNB-UHFFFAOYSA-N glyoxamide Chemical compound NC(=O)C=O AMANDCZTVNQSNB-UHFFFAOYSA-N 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000011630 iodine Chemical group 0.000 description 1
229910052740 iodine Chemical group 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000004688 microtubule Anatomy 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
230000000394 mitotic effect Effects 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
CBFZWGRQXZYRRR-UHFFFAOYSA-N pyridin-4-amine;hydrochloride Chemical compound Cl.NC1=CC=NC=C1 CBFZWGRQXZYRRR-UHFFFAOYSA-N 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
125000005425 toluyl group Chemical group 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Indole Compounds (AREA)

SK875-2002A 1999-12-23 2000-12-19 Substituted N-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect SK8752002A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19962300A DE19962300A1 (de)	1999-12-23	1999-12-23	Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
PCT/EP2000/012947 WO2001047913A2 (de)	1999-12-23	2000-12-19	Substituierte n-benzyl-indol-3-yl- glyoxylsäure-derivate antitumorwirkung

Publications (1)

Publication Number	Publication Date
SK8752002A3 true SK8752002A3 (en)	2003-01-09

Family

ID=7934006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK875-2002A SK8752002A3 (en)	1999-12-23	2000-12-19	Substituted N-benzyl-indol-3-yl glyoxylic acid derivatives having an anti-tumoral effect

Country Status (31)

Country	Link
US (1)	US6432987B2 (pl)
EP (1)	EP1240157B1 (pl)
JP (1)	JP2003519137A (pl)
KR (1)	KR100747425B1 (pl)
CN (1)	CN1283637C (pl)
AR (1)	AR027098A1 (pl)
AT (1)	ATE259364T1 (pl)
AU (1)	AU772745B2 (pl)
BG (1)	BG106924A (pl)
BR (1)	BR0016712A (pl)
CA (1)	CA2395259A1 (pl)
CO (1)	CO5251472A1 (pl)
CZ (1)	CZ20022094A3 (pl)
DE (2)	DE19962300A1 (pl)
DK (1)	DK1240157T3 (pl)
ES (1)	ES2215768T3 (pl)
HK (1)	HK1054038B (pl)
HU (1)	HUP0203716A3 (pl)
IL (1)	IL150235A0 (pl)
MX (1)	MXPA02006229A (pl)
NO (1)	NO324750B1 (pl)
NZ (2)	NZ533731A (pl)
PL (1)	PL195014B1 (pl)
PT (1)	PT1240157E (pl)
RU (1)	RU2266280C2 (pl)
SK (1)	SK8752002A3 (pl)
TR (1)	TR200400601T4 (pl)
TW (1)	TWI284128B (pl)
UA (1)	UA75060C2 (pl)
WO (1)	WO2001047913A2 (pl)
ZA (1)	ZA200204896B (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19814838C2 (de) *	1998-04-02	2001-01-18	Asta Medica Ag	Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DE19946301A1 (de) *	1998-04-02	2001-04-19	Asta Medica Ag	Indolyl-3-glyoxylsäure-Derivate mit therapeutisch wertvollen Eigenschaften
DE10037310A1 (de) *	2000-07-28	2002-02-07	Asta Medica Ag	Neue Indolderivate und deren Verwendung als Arzneimittel
DE10318611A1 (de) *	2003-04-24	2004-11-11	Elbion Ag	4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318609A1 (de) *	2003-04-24	2004-11-11	Elbion Ag	5-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
JP4878285B2 (ja) *	2003-06-05	2012-02-15	エテルナツェンタリスゲゼルシャフトミットベシュレンクテルハフツング	アポトーシス誘発作用を有するインドール誘導体
US7211588B2 (en) *	2003-07-25	2007-05-01	Zentaris Gmbh	N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
SG146624A1 (en)	2003-09-11	2008-10-30	Kemia Inc	Cytokine inhibitors
US7268159B2 (en) *	2003-09-25	2007-09-11	Wyeth	Substituted indoles
DE102004031538A1 (de) *	2004-06-29	2006-02-09	Baxter International Inc., Deerfield	Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
US8604055B2 (en)	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
MX2007007919A (es)	2004-12-31	2008-01-22	Reddy Us Therapeutics Inc	Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
JP5385605B2 (ja) *	2005-03-11	2014-01-08	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセットトランスポーターのモジュレーター
WO2008019357A2 (en) *	2006-08-07	2008-02-14	Ironwood Pharmaceuticals, Inc.	Indole compounds
CA2670778A1 (en) *	2006-11-28	2008-06-05	Ziopharm Oncology, Inc.	Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
CN107233337A (zh)	2009-04-29	2017-10-10	阿马里纳药物爱尔兰有限公司	含有epa和心血管剂的药物组合物以及使用其的方法
AR084433A1 (es)	2010-12-22	2013-05-15	Ironwood Pharmaceuticals Inc	Inhibidores de la faah y composiciones farmaceuticas que los contienen
JP5964965B2 (ja)	2011-08-18	2016-08-03	ドクターレディズラボラトリーズリミテッド	コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
IN2014CN02290A (pl)	2011-09-27	2015-06-19	Reddys Lab Ltd Dr

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1028812A (en) *	1962-08-28	1966-05-11	Ici Ltd	Indole derivatives
WO1993023374A1 (fr) *	1992-05-08	1993-11-25	Otsuka Pharmaceutical Factory, Inc.	Derive d'indole
IL109311A0 (en) *	1993-04-16	1994-07-31	Lilly Co Eli	1H-indole-3-acetamide sPla2 inhibitors
ES2122555T3 (es) *	1994-02-22	1998-12-16	Merrell Pharma Inc	Nuevos derivados indolicos utiles para tratar neoplasmas y trastornos relacionados con estrogenos.
EP1950200B1 (en) *	1994-04-01	2012-01-11	Eli Lilly And Company	[[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor
DE19636150A1 (de) *	1996-09-06	1998-03-12	Asta Medica Ag	N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
AU6229298A (en) *	1997-02-20	1998-09-09	Shionogi & Co., Ltd.	Indole dicarboxylic acid derivatives
US5972988A (en) *	1997-03-26	1999-10-26	Eli Lilly And Company	Method for treatment of chronic bronchitis using indole compounds
WO1998047507A1 (en) *	1997-04-24	1998-10-29	Shionogi & Co., Ltd.	Method for the treatment of stroke using n-heterocyclic glyoxylamide compounds
TW455581B (en) *	1997-06-26	2001-09-21	Lilly Co Eli	Process for preparing 4-substituted-1H-indole-3-glyoxamides
US6610728B2 (en) *	1997-08-28	2003-08-26	Eli Lilly And Company	Method for treatment of non-rheumatoid arthritis
AU9664198A (en) *	1997-09-26	1999-04-23	Eli Lilly And Company	Method for the treatment of cystic fibrosis
EP1030661A4 (en) *	1997-10-27	2002-07-17	Lilly Co Eli	N, N-DIETHYLGLYCOLAMIDOESTER OF INDOLS AS PRELIMINARY MEDICINE OF SPLA 2 INHIBITORS
WO1999021545A1 (en) *	1997-10-27	1999-05-06	Eli Lilly And Company	ISOPROPYL ESTER PRODRUGS OF INDOLE sPLA2 INHIBITORS
AU1200899A (en) *	1997-10-27	1999-05-17	Eli Lilly And Company	Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
WO1999024033A1 (en) *	1997-11-12	1999-05-20	Shionogi & Co., Ltd.	Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds
EP1039901A1 (en) *	1997-11-14	2000-10-04	Eli Lilly And Company	Treatment for alzheimer's disease
GEP20032920B (en) *	1998-02-25	2003-03-25	Genetics Inst	Inhibitors of Phospholipase Enzymes
DE19814838C2 (de) *	1998-04-02	2001-01-18	Asta Medica Ag	Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
DZ2770A1 (fr) *	1998-04-17	2003-12-01	Lilly Co Eli	Procédé de préparation de 1h-indol-3 glyoxamides substituées en position 4.
DE19818964A1 (de) *	1998-04-28	1999-11-04	Dresden Arzneimittel	Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
DK1076657T3 (da) *	1998-04-28	2004-11-08	Elbion Ag	Hidtil ukendte hydroxyindoler, deres anvendelse som inhibitorer for phosphodiesterase 4 og fremgangsmåde til deres fremstilling
EA200001140A1 (ru) *	1998-05-01	2001-04-23	Эли Лилли Энд Компани	СОЕДИНЕНИЯ-ИНГИБИТОРЫ sPLA2 ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ
ID27812A (id) *	1998-05-01	2001-04-26	Lilly Co Eli	ESTER PENGHAMBAT sPLA2
WO2000067802A1 (en) *	1999-05-10	2000-11-16	Protarga, Inc.	Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
TWI269654B (en) *	1999-09-28	2007-01-01	Baxter Healthcare Sa	N-substituted indole-3-glyoxylamide compounds having anti-tumor action

1999
- 1999-12-23 DE DE19962300A patent/DE19962300A1/de not_active Withdrawn
2000
- 2000-12-15 US US09/736,431 patent/US6432987B2/en not_active Expired - Fee Related
- 2000-12-19 TR TR2004/00601T patent/TR200400601T4/xx unknown
- 2000-12-19 AT AT00983349T patent/ATE259364T1/de not_active IP Right Cessation
- 2000-12-19 KR KR1020027007933A patent/KR100747425B1/ko not_active Expired - Fee Related
- 2000-12-19 BR BR0016712-6A patent/BR0016712A/pt not_active Application Discontinuation
- 2000-12-19 NZ NZ533731A patent/NZ533731A/en unknown
- 2000-12-19 AU AU20119/01A patent/AU772745B2/en not_active Ceased
- 2000-12-19 HK HK03106408.0A patent/HK1054038B/zh not_active IP Right Cessation
- 2000-12-19 PL PL355684A patent/PL195014B1/pl unknown
- 2000-12-19 DK DK00983349T patent/DK1240157T3/da active
- 2000-12-19 JP JP2001549383A patent/JP2003519137A/ja not_active Withdrawn
- 2000-12-19 ES ES00983349T patent/ES2215768T3/es not_active Expired - Lifetime
- 2000-12-19 DE DE50005284T patent/DE50005284D1/de not_active Expired - Fee Related
- 2000-12-19 MX MXPA02006229A patent/MXPA02006229A/es active IP Right Grant
- 2000-12-19 CZ CZ20022094A patent/CZ20022094A3/cs unknown
- 2000-12-19 PT PT00983349T patent/PT1240157E/pt unknown
- 2000-12-19 HU HU0203716A patent/HUP0203716A3/hu unknown
- 2000-12-19 IL IL15023500A patent/IL150235A0/xx not_active IP Right Cessation
- 2000-12-19 NZ NZ519977A patent/NZ519977A/en unknown
- 2000-12-19 SK SK875-2002A patent/SK8752002A3/sk unknown
- 2000-12-19 UA UA2002076107A patent/UA75060C2/uk unknown
- 2000-12-19 WO PCT/EP2000/012947 patent/WO2001047913A2/de not_active Ceased
- 2000-12-19 CN CNB008182094A patent/CN1283637C/zh not_active Expired - Fee Related
- 2000-12-19 RU RU2002120462/04A patent/RU2266280C2/ru not_active IP Right Cessation
- 2000-12-19 EP EP00983349A patent/EP1240157B1/de not_active Expired - Lifetime
- 2000-12-19 TW TW089127265A patent/TWI284128B/zh not_active IP Right Cessation
- 2000-12-19 CA CA002395259A patent/CA2395259A1/en not_active Abandoned
- 2000-12-22 CO CO00097375A patent/CO5251472A1/es not_active Application Discontinuation
- 2000-12-22 AR ARP000106916A patent/AR027098A1/es not_active Application Discontinuation
2002
- 2002-06-19 ZA ZA200204896A patent/ZA200204896B/en unknown
- 2002-06-21 NO NO20023039A patent/NO324750B1/no unknown
- 2002-07-16 BG BG106924A patent/BG106924A/bg unknown

Also Published As

Publication number	Publication date
PT1240157E (pt)	2004-06-30
KR20020063245A (ko)	2002-08-01
RU2266280C2 (ru)	2005-12-20
CO5251472A1 (es)	2003-02-28
CA2395259A1 (en)	2001-07-05
NZ519977A (en)	2004-08-27
ZA200204896B (en)	2002-12-20
AR027098A1 (es)	2003-03-12
PL355684A1 (pl)	2004-05-17
US6432987B2 (en)	2002-08-13
WO2001047913A2 (de)	2001-07-05
DE50005284D1 (de)	2004-03-18
IL150235A0 (en)	2002-12-01
PL195014B1 (pl)	2007-07-31
CN1420880A (zh)	2003-05-28
HUP0203716A3 (en)	2004-05-28
BG106924A (bg)	2003-04-30
AU772745B2 (en)	2004-05-06
AU2011901A (en)	2001-07-09
US20010014690A1 (en)	2001-08-16
UA75060C2 (en)	2006-03-15
CN1283637C (zh)	2006-11-08
TWI284128B (en)	2007-07-21
HK1054038B (zh)	2007-04-13
DK1240157T3 (da)	2004-06-14
WO2001047913A3 (de)	2002-04-25
EP1240157B1 (de)	2004-02-11
ES2215768T3 (es)	2004-10-16
NO324750B1 (no)	2007-12-03
RU2002120462A (ru)	2004-01-10
NO20023039D0 (no)	2002-06-21
DE19962300A1 (de)	2001-06-28
MXPA02006229A (es)	2003-01-28
TR200400601T4 (tr)	2004-04-21
NO20023039L (no)	2002-08-09
BR0016712A (pt)	2002-09-03
HK1054038A1 (en)	2003-11-14
NZ533731A (en)	2005-03-24
EP1240157A2 (de)	2002-09-18
JP2003519137A (ja)	2003-06-17
ATE259364T1 (de)	2004-02-15
HUP0203716A2 (hu)	2003-03-28
KR100747425B1 (ko)	2007-08-09
CZ20022094A3 (cs)	2002-10-16

Legal Events

Date	Code	Title	Description
2010-04-07	FB9A	Suspension of patent application procedure

Publication	Publication Date	Title
US6232327B1 (en)	2001-05-15	Indolyl-3-glyoxylic acid derivatives having antitumor action
US6344467B1 (en)	2002-02-05	N-substituted indole-3-glyoxylamides having anti-asthmatic, antiallergic and immunosuppressant/immuno-modulating action
KR100747425B1 (ko)	2007-08-09	항종양 효과를 갖는 치환된 ｎ-벤질-인돌-3-일 글리옥실산유도체
US7452910B2 (en)	2008-11-18	Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties
CN115677704B (zh)	2023-12-05	含有7H-吡咯并[2,3-d]嘧啶结构的组蛋白去乙酰化酶6抑制剂及制备方法和应用
CZ20003483A3 (cs)	2001-04-11	Deriváty indolyl-3-glyoxylové kyseliny s protinádorovým účinkem
MXPA00009646A (en)	2001-07-09	Indolyl-3-glyoxylic acid derivatives with antitumoral activity